DOCS shares closed at $30.71, down 2.51%, underperforming the S&P 500's 1.09% decline. The stock has gained 18.56% over the past month, outpacing the Medical sector's 2.68% advance, but this momentum masks deteriorating fundamentals heading into the Nov. 5 earnings report.
Analysts project EPS of $0.34 for Q4—a 24.44% year-over-year decline. For full fiscal 2026, consensus calls for $1.33 per share, down 12.5% from the prior year. This earnings contraction contradicts the company's ability to grow revenue, which is expected to rise 1.27% quarter-over-quarter and 4.79% for the full year to $675.74 million.
The math here matters to your portfolio: Doximity trades at a forward P/E of 23.61, a 29% discount to the Medical Info Systems industry average of 33.2. That looks cheap until you consider the PEG ratio of 13.73—more than four times the industry average of 3.14. Investors are paying an elevated multiple relative to actual growth. With earnings falling while revenue inches forward, the company is caught in a profitability squeeze.
The Zacks Rank of #3 (Hold) signals no fresh conviction, and consensus EPS estimates have remained flat over the past 30 days. That stillness before an earnings miss is often a red flag. Watch for any negative guidance or commentary on customer acquisition and retention when DOCS reports on Nov. 5. A miss on the magnitude of the current forecast—or worse, a reduction in forward guidance—could crack the stock below $30 and trigger a retest of lower support.
